Focus on anti-atherosclerotic therapy.
Calcium antagonists (CA) exert an anti-atherosclerotic effect in cholesterol-fed rabbits through reduction of cholesterol accumulation in the arterial wall. Further studies in our Institute indicate that verapamil-like compounds and diltiazem stimulate receptor-mediated LDL uptake by human fibroblasts in culture, while nifedipine-like compounds and flunarizine are inactive. Verapamil and diltiazem stimulated LDL-receptor activity also in cells from a heterozygous FH patient, while they were inactive in a receptor defective homozygous FH patient. A basic group needs to be present on the CA molecule to modulate the LDL receptor expression. Preliminary data in our laboratory suggest that some CA can achieve concentrations in the aortic wall likely to exert effects on LDL receptors. This stimulatory activity may improve lipid metabolism in the arterial wall.
Bernini
F
F
Istituto di Scienze Farmacologiche, Università di Milano.
Paoletti
R
R
D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D002784:Cholesterol / Q000378:metabolism*; D002788:Cholesterol Esters / Q000378:metabolism; D004195:Disease Models, Animal; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000235:genetics / Q000378:metabolism*; D006951:Hyperlipoproteinemias / Q000150:complications / Q000378:metabolism*; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008955:Models, Cardiovascular; D011817:Rabbits; D011973:Receptors, LDL / Q000187:drug effects / Q000378:metabolism*
D002121:Calcium Channel Blockers; D002788:Cholesterol Esters; D008077:Lipoproteins, LDL; D011973:Receptors, LDL; D002784:Cholesterol